Pequot Health Care Opioid Analgesic Quantity Program*
|
|
|
- Dylan French
- 6 years ago
- Views:
Transcription
1 Pequot Health Care 1 Annie George Drive Mashantucket, CT Phone: Fax: Pequot Health Care Opioid Analgesic Quantity Program* Effective January 2018 *Quantity Program limits apply to generic versions of drugs where applicable. For Group 2 Medications contact our Pharmacy Benefits Department at or Pequot_PBM@prxn.com or the number on the back of your card GROUP 1 MEDICATIONS Medications in GROUP I consist of drug categories that have stand-alone limitations based on FDA-approved drug labeling, meaning that once the maximum drug limit is reached the member is responsible for the entire cost of the medication. Prior Authorization is required for quantities exceeding limits. Immediate-Release Codeine sulfate tab 15mg 42 tablets** 42 tablets** Codeine sulfate tab 30mg 42 tablets** 42 tablets** Codeine sulfate tab 60mg 42 tablets** 42 tablets** Hydromorphone soln 1mg/ml 600 ml 1800ml Hydromorphone supp 3mg 120 supp 360 supp Hydromorphone tab 2mg 180 tablets 540 tablets Hydromorphone tab 4mg 180 tablets 540 tablets Hydromorphone tab 8mg 180 tablets 540 tablets Levorphanol tab 2mg 120 tablets 360 tablets Meperidine oral soln 50mg/5ml 90 ml** 90 ml** Meperidine tablet 50mg 18 tablets** 18 tablets** Meperidine tablet 100mg 18 tablets** 18 tablets** Morphine sulfate (conc) oral soln 20mg/ml 180ml 540ml Morphine sulfate oral soln 10mg/5ml 900ml 2700ml Morphine sulfate oral soln 20mg/5ml 900ml 2700ml Morphine sulfate sup 5mg 180 supp 540 supp Morphine sulfate sup 10mg 180 supp 540 supp Morphine sulfate sup 20mg 180 supp 540 supp Morphine sulfate sup 30mg 180 supp 540 supp Morphine sulfate tablet 15mg 180 tablets 540 tablets Morphine sulfate tablet 30mg 180 tablets 540 tablets Oxycodone (conc) soln 20mg/ml 180ml 540ml Oxycodone soln 5mg/5ml 900ml 2700ml Oxycodone capsule 5mg 180 capsules 540 capsules Oxycodone tablet 5mg 180 tablets 540 tablets Oxycodone tablet 10mg 180 tablets 540 tablets
2 GROUP 1 MEDICATIONS Medications in GROUP I consist of drug categories that have stand-alone limitations based on FDA-approved drug labeling, meaning that once the maximum drug limit is reached the member is responsible for the entire cost of the medication. Prior Authorization is required for quantities exceeding limits. DRUG CLASS DRUG CLASS 1 MONTH SUPPLY 3 MONTH SUPPLY Immediate-Release Extended-Release Oxycodone tablet 15mg 180 tablets 540 tablets Oxycodone tablet 20mg 180 tablets 540 tablets Oxycodone tablet 30mg 180 tablets 540 tablets Oxaydo tablet 5mg 540 tablets 1620 tablets Oxaydo tablet 7.5mg 360 tablets 1080 tablets Oxymorphone tablet 5mg 180 tablets 540 tablets Oxymorphone tablet 10mg 180 tablets 540 tablets Pentazocine/naloxone 50/0.5mg 180 tablets** 180 tablets** Tapentadol tablet 50mg 360 tablets 1080 tablets Tapentadol tablet 75mg 240 tablets 270 tablets Tapentadol tablet 100mg 180 tablets 540 tablets Tramadol tablet 50mg 180 tablets 540 tablets Arymo ER 15mg 90tablets 270 tablets Arymo ER 30mg 90 tablets 270 tablets Arymo ER 60mg 90 tablets 270 tablets Belbuca 75mcg 60 films 180 films Belbuca 150mcg 60 films 180 films Belbuca 300mcg 60 films 180 films Belbuca 450mcg 60 films 180 films Belbuca 600mcg 60 films 180 films Belbuca 750mcg 60 films 180 films Belbuca 900mcg 60 films 180 films Butrans 5mcg/hr 4 patches 12 patches Butrans 7.5mcg/hr 4 patches 12 patches Butrans 10mcg/hr 4 patches 12 patches Butrans 15 mcg/hr 4 patches 12 patches Butrans 20 mcg/hr 4 patches 12 patches Conzip 100mg 30 capsules 90 capsules Conzip 200mg 30 capsules 90 capsules Conzip 300mg 30 capsules 90 capsules Duragesic patch 12mcg 10 patches 30 patches Duragesic patch 25mcg 10 patches 30 patches Duragesic patch 37.5mcg 10 patches 30 patches Duragesic patch 50mcg 10 patches 30 patches Duragesic patch 62.5mcg 10 patches 30 patches
3 GROUP 1 MEDICATIONS Medications in GROUP I consist of drug categories that have stand-alone limitations based on FDA-approved drug labeling, meaning that once the maximum drug limit is reached the member is responsible for the entire cost of the medication. Prior Authorization is required for quantities exceeding limits. Extended-Release Duragesic patch 75mcg 10 patches 30 patches Duragesic patch 87.5mcg 10 patches 30 patches Duragesic patch 100mcg 10 patches 30 patches Embeda 20/0.8mg 60 capsules 180 capsules Embeda 30/1.2mg 60 capsules 180 capsules Embeda 50/2mg 60 capsules 180 capsules Embeda 60/2.4mg 60 capsules 180 capsules Embeda 80/3.2mg 60 capsules 180 capsules Embeda 100/4mg 60 capsules 180 capsules Exalgo 8mg 30 tablets 90 tablets Exalgo12mg 30 tablets 90 tablets Exalgo 16mg 30 tablets 90 tablets Exalgo 32mg 30 tablets 90 tablets Hysingla ER 20mg 30 tablets 90 tablets Hysingla ER 30mg 30 tablets 90 tablets Hysingla ER 40mg 30 tablets 90 tablets Hysingla ER 60mg 30 tablets 90 tablets Hysingla ER 80mg 30 tablets 90 tablets Hysingla ER 100mg 30 tablets 90 tablets Hysingla ER 120mg 30 tablets 90 tablets Kadian 10mg 60 capsules 180 capsules Kadian 20mg 60 capsules 180 capsules Kadian 30mg 60 capsules 180 capsules Kadian 40mg 60 capsules 180 capsules Kadian 50mg 60 capsules 180 capsules Kadian 60mg 60 capsules 180 capsules Kadian 80mg 60 capsules 180 capsules Kadian 100mg 60 capsules 180 capsules Kadian 200mg 60 capsules 180 capsules Methadone tablet 5mg 90 tablets 270 tablets Methadone tablet 10mg 90 tablets 270 tablets Methadone oral soln 5mg/5ml 450 ml 1350 ml Methadone oral soln 10mg/5ml 450 ml 1350 ml MorphaBond 15mg 60 tablets 180 tablets MorphaBond 30mg 60 tablets 180 tablets
4 GROUP 1 MEDICATIONS Medications in GROUP I consist of drug categories that have stand-alone limitations based on FDA-approved drug labeling, meaning that once the maximum drug limit is reached the member is responsible for the entire cost of the medication. Prior Authorization is required for quantities exceeding limits. Extended-Release MorphaBond 60mg 60 tablets 180 tablets MorphaBond 100mg 60 tablets 180 tablets MS Contin 15mg 90 tablets 270 tablets MS Contin 30mg 90 tablets 270 tablets MS Contin 60mg 90 tablets 270 tablets MS Contin 100mg 90 tablets 270 tablets MS Contin 200mg 90 tablets 270 tablets Nucynta ER 50mg 60 tablets 180 tablets Nucynta ER 100mg 60 tablets 180 tablets Nucynta ER 150mg 60 tablets 180 tablets Nucynta ER 200mg 60 tablets 180 tablets Nucynta ER 250mg 60 tablets 180 tablets Opana ER 5mg 60 tablets 180 tablets Opana ER 7.5mg 60 tablets 180 tablets Opana ER 10mg 60 tablets 180 tablets Opana ER 15mg 60 tablets 180 tablets Opana ER 20mg 60 tablets 180 tablets Opana ER 30mg 60 tablets 180 tablets Opana ER 40mg 60 tablets 180 tablets Oxycontin 10mg 60 tablets 180 tablets Oxycontin 15mg 60 tablets 180 tablets Oxycontin 20mg 60 tablets 180 tablets Oxycontin 30mg 60 tablets 180 tablets Oxycontin 40mg 60 tablets 180 tablets Oxycontin 60mg 60 tablets 180 tablets Oxycontin 80mg 120 tablets 360 tablets Tramadol ER 100mg 30 tablets 90 tablets Tramadol ER 150mg 30 capsules 90 capsules Tramadol ER 200mg 30 tablets 90 tablets Tramadol ER 300mg 30 tablets 90 tablets Troxyca ER 10mg/1.2mg 60 capsules 180 capsules Troxyca ER 20mg/2.4mg 60 capsules 180 capsules Troxyca ER 30mg/3.6mg 60 capsules 180 capsules Troxyca ER 40mg/4.8mg 60 capsules 180 capsules Troxyca ER 60mg/7.2mg 60 capsules 180 capsules
5 Troxyca ER 80mg/9.6mg 60 capsules 180 capsules GROUP 1 MEDICATIONS Medications in GROUP I consist of drug categories that have stand-alone limitations based on FDA-approved drug labeling, meaning that once the maximum drug limit is reached the member is responsible for the entire cost of the medication. Prior Authorization is required for quantities exceeding limits. Extended-Release Vantrela ER 15mg 60 tablets 180 tablets Vantrela ER 30mg 60 tablets 180 tablets Vantrela ER 45mg 60 tablets 180 tablets Vantrela ER 60mg 60 tablets 180 tablets Vantrela ER 90mg 60 tablets 180 tablets Xtampza ER 9mg 60 capsules 180 capsules Xtampza ER 13.5mg 60 capsules 180 capsules Xtampza ER 18mg 60 capsules 180 capsules Xtampza ER 27mg 60 capsules 180 capsules Xtampza ER 36mg 60 capsules 180 capsules Zohydro ER 10mg 60 capsules 180 capsules Zohydro ER 15mg 60 capsules 180 capsules Zohydro ER 20mg 60 capsules 180 capsules Zohydro ER 30mg 60 capsules 180 capsules Zohydro ER 40mg 60 capsules 180 capsules Zohydro ER 50mg 60 capsules 180 capsules Miscellaneous Butorphanol tartrate nasal spray 10mg/ml 2 bottles 6 bottles Methadone Intensol oral concentrate 10mg/ml 30ml 30ml Methadose oral concentrate 10mg/ml 30ml 30ml Methadose dispersible tablet 40mg 9 tablets 9 tablets Stadol NS (Butorphanol tartrate) 10mg/ ml 6ml / 25 Days 18ml/ 75 Days Xartemis XR 7.5mg-325mg 120 tablets** 120 tablets**
6 GROUP 2 MEDICATIONS Medications in GROUP 2 consist of drug categories that have quantity limitations based on opioid amount of 90 morphine equivalents per day; 4g acetaminophen (APAP) OR aspirin (ASA); 3200mg ibuprofen (IBU); OR the maximum FDA-approved quantity limit according to the products prescribing label. GROUP 2 medications accumulate drug limitations based on one of the following 4 categories: 1)APAP-containing solutions, suspensions, elixers accumulate together; 2)APAP-containing tablets and capsules accumulate together; 3)ASA-containing tablets and capsules accumulate together; 4) IBU-containing tablets accumulate together. Prior Authorization is required for quantities exceeding limits. Opioid Analgesic Combination Products (w/apap, ASA or IBU) APAP/codeine soln 120mg-12mg/5ml 2700 ml (max 360mg codeine/day) 8100 ml Hydrocodone/APAP soln 7.5mg-325mg/15ml Hydrocodone/APAP elixer 10mg-300mg/15ml Hydrocodone/APAP soln 10mg-325mg/15ml Oxycodone/APAP soln 5mg-325mg/5ml APAP/codeine tablet 300mg-15mg APAP/codeine tablet 300mg-30mg APAP/codeine tablet 300mg-60mg 2700 ml (max 90ml/day) 2025 ml (max 67.5ml/day) 2700 ml (max 90ml/day) 1800 ml (max 60ml/day) 400 tablets (max 360mg codeine/day) 360 tablets (max 360mg codeine/day) 180 tablets (max 360mg codeine/day) 8100 ml 6075 ml 8100 ml 5400 ml 1200 tablets 1080 tablets 540 tablets APAP/caffeine/dihydrocodeine capsule 320 mg- 30mg-16mg APAP/caffeine/dihydrocodeine tablet 712.8mg-60mg-32mg Hydrocodone/APAP tablet 2.5mg-325mg 300 capsules 900 capsules (max 10/day) 150 tablets (max 5/day) 450 tablets 360 tablets (max 1080 tablets 12/day) Hydrocodone/APAP tablet 5mg-300mg 240 tablets (max 8/day) 720 tablets Hydrocodone/APAP tablet 5mg-325mg 240 tablets (max 8/day) 720 tablets Hydrocodone/APAP tablet 7.5mg-300mg 180 tablets (max 6/day) 540 tablets Hydrocodone/APAP tablet 7.5mg-325mg 180 tablets (max 6/day) 540 tablets Hydrocodone/APAP tablet 10mg-300mg 180 tablets (max 6/day) 540 tablets Hydrocodone/APAP tablet 10mg-325mg 180 tablets (max 6/day) 540 tablets Oxycodone/APAP tablet 2.5mg-325mg 360 tablets (max 1080 tablets 12/day) Oxycodone/APAP tablet 5mg-300mg 360 tablets (max 1080 tablets
7 12/day) Oxycodone/APAP tablet 5mg-325mg 360 tablets (max 1080 tablets 12/day) Oxycodone/APAP tablet 7.5mg-300mg 240 tablets (max 8/day) 720 tablets Oxycodone/APAP tablet 7.5mg-325mg 240 tablets (max 8/day) 720 tablets Oxycodone/APAP tablet 10mg-300mg 180 tablets (max 6/day) 540 tablets Oxycodone/APAP tablet 10mg-325mg 180 tablets (max 6/day) 540 tablets Tramadol/APAP tablet 37.5mg-325mg (MAX 5 DAY SUPPLY) 40 tablets (max 6/day)** 40 tablets** Oxycodone/ASA tablet mg-325mg 360 tablets (max 12/day) 1080 tablets
8 GROUP 2 MEDICATIONS Medications in GROUP 2 consist of drug categories that have quantity limitations based on opioid amount of 90 morphine equivalents per day; 4g acetaminophen (APAP) OR aspirin (ASA); 3200mg ibuprofen (IBU); OR the maximum FDA-approved quantity limit according to the products prescribing label. GROUP 2 medications accumulate drug limitations based on one of the following 4 categories: 1)APAP-containing solutions, suspensions, elixers accumulate together; 2)APAP-containing tablets and capsules accumulate together; 3)ASA-containing tablets and capsules accumulate together; 4) IBU-containing tablets accumulate together. Prior Authorization is required for quantities exceeding limits. Opioid Analgesic Combination Products (w/apap, ASA or IBU) Hydrocodone/IBU tablet 2.5mg-200mg (MAX 10 DAY SUPPLY) Hydrocodone/IBU tablet 5mg-200mg (MAX 10 DAY SUPPLY) Hydrocodone/IBU tablet 7.5mg-200mg (MAX 10 DAY SUPPLY) Hydrocodone/IBU tablet 10mg-200mg (MAX 10 DAY SUPPLY) Oxycodone/IBU tablet 5mg-400mg (MAX 7 DAY SUPPLY) 50 tablets (max 5/day)** 50 tablets (max 5/day)** 50 tablets (max 5/day) ** 50 tablets (max 5/day) ** 28 tablets (max 4/day) ** 50 tablets** 50 tablets** 50 tablets** 50 tablets** 28 tablets** **Product is indicated for short-term acute use only; thus, 30-day and 90-day limits are the same.
Opioid Management Program May 2018
Opioid Management Program May 2018 What Is the Opioid Management Program? This program is based on guidelines developed by the U.S. Centers for Disease Control and Prevention (CDC). It consists of daily
Opioid Management Program October 2018
Opioid Management Program October 2018 What Is the Opioid Management Program? This program is based on guidelines developed by the U.S. Centers for Disease Control and Prevention (CDC). It consists of
Generic Label Name Drug Strength Dosage Form Example Product (s) MME/Unit ACETAMINOPHEN WITH CODEINE
STATE OF TENNESSEE DEPARTMENT OF FINANCE AND ADMINISTRATION DIVISION OF HEALTH CARE FINANCE AND ADMINISTRATION BUREAU OF TENNCARE 3 Great Circle Road NASHVILLE, TENNESSEE 37243 This notice is to advise
20/0.8mg, 30/1.2mg, Films 90 MME/day Belbuca (buprenorphine) 75mcg, 150mcg, 300mcg, 450mcg 60 units per 90 days
Pre - PA Allowance Quantity Extended Release Tablets or Capsules 90 MME/day Medication Strength Avinza (morphine) 60mg, 75mg, 90mg Embeda (morphine /naltrexone) 50/2mg, 60/2.4mg, 80/3.2mg Exalgo (hydromorphone)
Carefirst. +.V Family of health care plans
Family of health care plans Prior Authorization Form 1361M Opioids ER MME Limit and Post Limit This fax machine is located in a secure location as required by HPAA regulations. Complete/review information,
APPROVED PA CRITERIA. Initial Approval: January 10, 2018 Revised Dates: April 11, 2018 CRITERIA FOR PRIOR AUTHORIZATION
Initial Approval: January 10, 2018 Revised Dates: April 11, 2018 CRITERIA FOR PRIOR AUTHORIZATION PROVIDER GROUP Pharmacy Opioid Products Indicated for Pain Management MANUAL GUIDELINES All dosage forms
Capital BlueCross Open/Closed Formulary Update (1 st Quarter 2017)
Capital BlueCross Open/Closed Formulary Update (1 st Quarter 2017) The Capital BlueCross formulary is a reference list of prescription drugs that contains a wide range of generic and brand drugs that have
Long-Acting Opioid Analgesics
Market DC Long-Acting Opioid Analgesics Override(s) Prior Authorization Step Therapy Quantity Limit Approval Duration Initial request: 3 months Maintenance Therapy: Additional prior authorization required
Long-Acting Opioid Analgesics
Market DC Long-Acting Opioid Analgesics Override(s) Prior Authorization Step Therapy Quantity Limit Approval Duration Initial request: 3 months Maintenance Therapy: Additional prior authorization required
Prior Authorization for Opioid Products Indicated for Pain Management
Kansas Medical Assistance Program PA Phone 800-933-6593 PA Fax 800-913-2229 Amerigroup PA Pharmacy Phone 855-201-7170 PA Pharmacy Fax 800-601-4829 Sunflower PA Pharmacy Phone 877-397-9526 PA Pharmacy Fax
Cigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Controlled Substance Analgesic and Narcotic Antagonist Quantity Limitations Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing
Pharmacy Medical Necessity Guidelines: Opioid Analgesics
Pharmacy Medical Necessity Guidelines: Effective: January 1, 2019 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
Prior Authorization Guideline
Guideline GL-35952 Opioid Quantity Limit Overrides Formulary OptumRx Formulary Note: Approval Date 7/10/2017 Revision Date 7/10/2017 Technician Note: P&T Approval Date: 2/16/2010; P&T Revision Date: 7/12/2011
QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA
DRUG CLASS QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA EXTENDED-RELEASE OPIOID ANALGESICS BRAND NAME (generic) ARYMO ER (morphine sulfate extended-release tablets) AVINZA (morphine extended-release
Xyrem (Sodium Oxybate)
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Opioid Analgesics. Recommended starting dose for opioid-naïve patients
Opioid Analgesics Goals: Restrict use of opioid analgesics to OHP-funded conditions with documented sustained improvement in pain and function and with routine monitoring for opioid misuse and abuse. Promote
Opioids, Extended Release (ER) Quantity Limit Criteria Program Summary
Opioids, Extended Release (ER) Quantity Limit Criteria Program Summary This program applies to Commercial, GenPlus, NetResults A series, Netresults F series and Health Insurance Marketplace. Belbuca is
UnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 3053-9 Program Step Therapy Long Acting Opioids Medication Includes both brand and generic versions of the listed products unless
Opioid Analgesic/Opioid Combination Products
Market DC Opioid Analgesic/Opioid Combination Products Override(s) Quantity Limit Approval Duration 1 year Generic Name Brand Name Quantity Limit APAP/Caf/Dihydrocodeine 320.5mg/30mg/16mg APAP/Caf/Dihydrocodeine
Diabetes Fortamet (metformin ER), Glumetza (metformin ER) generic of Glucophage XR (metformin ER) preferred
Pennsylvania Employees Benefit Trust Fund (PEBTF) and n-medicare Eligible Retired Employees Health Program (REHP), Step Therapy and Quantity Limit List Your doctor needs to get prior authorization for
MEDICARE Program Policies & Procedures POLICY NUMBER: Medicare D-111
POLICY: Medicare Part D Formulary-Level Cumulative Opioid and Opioid/Buprenorphine POS Edits MEDICARE Program Policies & Procedures POLICY NUMBER: Medicare D-111 Policy for contracts H3351, S3521 and H3335
EXTENDED RELEASE OPIOID DRUGS
RATIONALE FOR INCLUSION IN PA PROGRAM Background Hydrocodone (Hysingla ER, Vantrela ER, Zohydro ER), hydromorphone (Exalgo), morphine sulfate (Arymo ER, Avinza, Embeda, Kadian, MorphaBond, MS Contin),
Drug Name (specify drug) Quantity Frequency Strength
Prior Authorization Form GEHA FEDERAL - STANDARD OPTION 1363-M Opioids IR MME Limit and Post Limit This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary October 1, 2018 Updates. Formulary. Alternatives
PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select October 1, 2018 Updates Drug Name efavirenz 600mg (Brand = Sustiva ) trientine (Brand = Syprine ) hydrocortisone lot 0.1% (Brand = Locoid ) sumatriptan-naproxen
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Opioids, Extended Release (ER) Page 1 of 12 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Opioids, Extended Release (ER) Prime Therapeutics will review Prior Authorization
Drug Name (specify drug) Quantity Frequency Strength
Prior Authorization Form MEDICA HEALTH PLAN IA EXCHANGE 1362-M Opioids IR Labeling Post Limit (HMF) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
STEP THERAPY WITH QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA. AVINZA (morphine extended-release capsules)
Carelirst. +.V Family of health care plans cvs caremarktm STEP THERAPY WITH QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA DRUG CLASS EXTENDED-RELEASE OPIOID ANALGESICS BRAND NAME* (generic)
Opiate/Benzodiazepine/Muscle Relaxant Combinations
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Opiate/Benzodiazepine/Muscle Relaxant Combinations Clinical Edit Information Included in this Document Drugs requiring prior authorization:
Prescription Drugs with Dispensing Limits or Prior Authorization Requirements
Prescription Drugs with s or Requirements MHBP provides benefits for most covered prescription drugs for up to a 30-day supply when purchased at a retail pharmacy, and receive up to a 90 day supply for
UnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 3053-7 Program Step Therapy Long Acting Opioids Medication Includes both brand and generic versions of the listed products unless
: Opioid Quantity Limits
March 7, 2017 2017-09: Opioid Quantity Limits The Louisiana Department of Health (LDH), in conjunction with the Louisiana Medicaid Drug Utilization Review (DUR) Board, has revised quantity limits for selected
New Hampshire Healthy Families CLINICAL POLICY
New Hampshire Healthy Families CLINICAL POLICY DEPARTMENT: Pharmacy DOCUMENT NAME: Opioid Analgesics PAGE: 1 o f 6 REFERENCE NUMBER: NH.PPA.13 EFFECTIVE DATE: 6/1/2016 REPLACES DOCUMENT: N/A RETIRED: REVIEWED:
Opioid Analgesic/Opioid Combination Products
Opioid Analgesic/Opioid Combination Products Override(s) Quantity Limit Approval Duration 1 year Generic Name Brand Name Quantity Limit 320.5mg/30mg/16mg 356.4mg/30mg/16mg 325mg/30mg/16mg Trezix (new formulation)
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.259 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
Long-Acting Opioid. Policy Number: Last Review: 12/2017 Origination: 09/2013 Next Review: 09/2018
Long-Acting Opioid Policy Number: 5.02.519 Last Review: 12/2017 Origination: 09/2013 Next Review: 09/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for long-acting
Cigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Opioid Therapy Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 7 References... 7 Effective Date..1/1/2018 Next
AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization
AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization Policy applies to all formulary and non-formulary schedules II V opioid narcotics, including tramadol and codeine, as
Texas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Prior Authorization Opioid Overutilization 2017
Drugs Requiring Prior Authorization Label Name ACETAMINOPHEN/CAFFEINE/DIHYDROCODEINE CAPSULE ACETAMINOPHEN/CODEINE SOLUTION ACETAMINOPHEN/CODEINE TABLET ASCOMP/CODEINE CAPSULE BUTALBITAL/CAFFEINE/ACETAMINOPHEN/CODEINE
Morphine Sulfate Hydromorphone Oxymorphone
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.02.33 Subject: Morphine Drug Class Page: 1 of 8 Last Review Date: June 19, 2015 Morphine Sulfate Hydromorphone
Extended Release Opioid Drugs
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Section: Prescription Drugs Effective Date: January 1, 2019 Subject: Extended Release Opioid Drugs Page:
Session II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids
Learning Objectives for Session II Session II Best Practices for How to Start Therapy with ER/LA Opioids, How to Stop, and What to Do in Between Upon completion of this module, the participants will be
15 mg morphine 10 mg hydrocodone
Cari untuk: Cari Cari 15 mg morphine 10 mg hydrocodone 3-2-2013 Convert From CALCULATED MORPHINE EQUIVALENT BY RESOURCE: Average ( mg ) Range ( mg ) Standard Deviation of Sample ( mg ) Hydrocodone. I usually
Drug Use Evaluation: Short Acting Opioids (SAO)
Drug Use Evaluation: Short Acting Opioids (SAO) Summary Short acting opioid analgesics are one of the most prescribed (top 10) and highest cost (top 20) medication classes for the Oregon Fee For Service
Extended Release Opioid Drugs
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.61 Subject: Extended Release Opioid Drugs Page: 1 of 14 Last Review Date: March 16, 2018 Extended
Medication Policy Manual. Topic: Extended-release (ER) Opioid Medication Products for Pain. Date of Origin: January 1, 2018
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Topic: Extended-release (ER) Opioid Medication Products for Pain Policy No: dru515 Date of Origin: January 1,
How To Green My Pharmacy. Prepared and presented by Luna El Bizri,Pharm-D, Community Pharmacist
How To Green My Pharmacy Prepared and presented by Luna El Bizri,Pharm-D, Community Pharmacist Learning Objectives At the end of this presentation, pharmacists will be able to : 1. Understand the negative
Pharmacy Management Drug Policy
SUBJECT: Opioid Management Health and Safety Program POLICY NUMBER: PHARMACY-34 EFFECTIVE DATE: 6/2007 LAST REVIEW DATE: 07/01/2018 If the member s subscriber contract excludes coverage for a specific
Medication Policy Manual. Date of Origin: January 1, Topic: Extended-release (ER) Opioid Medication Products for Pain
Medication Policy Manual Topic: Extendedrelease (ER) Opioid Medication Products for Pain Policy No: dru515 Date of Origin: January 1, 2018 Committee Approval Date: January 19. 2018 Next Review Date: December
Drug Formulary Commission
Drug Formulary Commission Bureau of Health Care Safety and Quality Department of Public Health December 15, 2016 Slide 1 Presentation Agenda Draft Formulary (105 CMR 720) Schedule Amendments Comments Guidance
Introduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics
Introduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics In April 2011, FDA announced the elements of a Risk Evaluation and Mitigation Strategy
Disposal of Unused Medicines: What You Should Know
1 of 8 3/12/16 11:14 PM U.S. Food and Drug Administration Protecting and Promoting Your Health Disposal of Unused Medicines: What You Should Know Topics on this page Overview List of Medicines Recommended
Embeda. Embeda (morphine sulfate and naltrexone hydrochloride) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.39 Subject: Embeda Page: 1 of 6 Last Review Date: March 18, 2016 Embeda Description Embeda (morphine
Methadone. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.41 Subject: Methadone Page: 1 of 8 Last Review Date: March 18, 2016 Methadone Description Dolophine
Extended Release Opioid Drugs
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.61 Subject: Extended Release Opioid Drugs Page: 1 of 13 Last Review Date: December 8, 2017 Extended
Opioid Capture in the AHSQC Can we reduce use by measuring it? Michael Reinhorn MD, MBA, FACS Dept of Surgery, Newton Wellesley Hospital
Opioid Capture in the AHSQC Can we reduce use by measuring it? Michael Reinhorn MD, MBA, FACS Dept of Surgery, Newton Wellesley Hospital Disclosure Davol/Bard Consultant Medtronic Physician Advisory Honorarium
Disposal of Unused Medicines: What You Should Know
1 of 8 04/27/2016 1:37 AM U.S. Food and Drug Administration Protecting and Promoting Your Health Disposal of Unused Medicines: What You Should Know Topics on this page (http://www.fda.gov/aboutfda/aboutthiswebsite
Opioid Analgesic Treatment Worksheet
Opioid Analgesic Treatment Worksheet Aetna Better Health of Louisiana Fax: 1 844 699 2889 www.aetnabetterhealth.com/louisiana/providers/pharmacy LA Legacy Fee for Service (FFS) Medicaid Fax: 1 866 797
Immediate Release Opioid Analgesics (Brand and Generic): Acute Pain Duration Limit with MME Limit and Post Limit Policy
BENEFIT APPLICATION DRUG POLICY Immediate Release Opioid Analgesics (Brand and Generic): Acute Pain Duration Limit with MME Limit and Post Limit Policy Benefit determinations are based on the applicable
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Opioid Immediate Release Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Opioid Immediate Release Prime Therapeutics will review Prior Authorization
Opioid Prescribing Guidelines for Patients in the Emergency Department
Opioid Prescribing Guidelines for Patients in the Emergency Department and Immediate Care Centers These guidelines are meant to assist clinicians in treating patients with acute and chronic pain in the
10 mg hydrocodone equals how much oxycodone
Cari untuk: Cari Cari 10 mg hydrocodone equals how much oxycodone Posts about dilaudid 8 vs oxycodone 30 written by buyprescriptionmedication. Can you help me with the conversion of Oxycodone IR (5mg tab)
Demerol (meperidine oral tablet, oral solution), Meperitab (oral tablet)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subsection: Analgesics and Opioids Original Policy Date: May 8, 2015 Subject: Meperidine Page: 1 of 5 Last
Addressing Drug Diversion
Webinar Objectives Addressing Drug Diversion Bernice Burkarth, MD, HMDC, FAAHPM BBurkarth@treasurehealth.org October12, 2017 At the completion of this Webinar, participants will be able to: Identify tools
Session VI. Presenter Disclosure Information. Learning Objectives for Session VI. Prescribing Information. Prescribers Must Be Knowledgeable
SAFE Opioid Prescribing Strategies. Assessment. Fundamentals. Education 4 6pm SPEAKERS Charles Argoff, MD, FABPM Michael Brennan, MD, FACP, FASAM Jeffrey Gudin, MD Presenter Disclosure Information The
Drug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA opioid analgesics) Avinza Butrans
FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics 7/9/2012 Drug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA
1/29/2013. Schedule II Controlled Substances: Basics and Beyond. Controlled Substances. Controlled Substances, Schedule I
chedule II Controlled ubstances: Basics and Beyond James L. Besier, Ph.D., R.Ph., FAHP Adjunct Associate Professor College of Nursing Adjunct Assistant Professor James L. Winkle College of Pharmacy University
DURATION LIMIT WITH QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA IMMEDIATE-RELEASE OPIOID ANALGESICS (BRAND AND GENERIC)*
Carelirst. +.V Family of health care plans cvs caremarktm DURATION LIMIT WITH QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA DRUG CLASS generic name, dosage form IMMEDIATE-RELEASE OPIOID ANALGESICS
Conversion chart from fentanyl to opana er
Conversion chart from fentanyl to opana er (e.g., Nucynta). Both opioid products involved in conversion are one of the following: morphine, oxycodone, oxymorphone, hydromorphone (not extended- release),
Opioid Analgesic Treatment Worksheet
Opioid Analgesic Treatment Worksheet Aetna Better Health of Louisiana Fax: 1 844 699 2889 www.aetnabetterhealth.com/louisiana/providers/pharmacy LA Legacy Fee for Service (FFS) Medicaid Fax: 1 866 797
Duragesic patch. Duragesic patch (fentanyl patch) Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.31 Subject: Duragesic patch Page: 1 of 6 Last Review Date: March 18, 2016 Duragesic patch Description Duragesic patch (fentanyl
ER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care
ER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care In August 2014, the Food and Drug Administration (FDA) updated the Extended- Release/Long Acting Opioids REMS Blueprint (BP). CO*RE has
Nucynta IR/ Nucynta ER (tapentadol immediate-release and extendedrelease)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Nucynta Page: 1 of 7 Last Review Date: March 18, 2016 Nucynta Description Nucynta IR/ Nucynta
Proposed Changes to Existing Measure for HEDIS : Use of Opioids at High Dosage (UOD)
Proposed Changes to Existing Measure for HEDIS 1 2020: Use of Opioids at High Dosage (UOD) NCQA seeks comments on proposed revisions to the Use of Opioids at High Dosage HEDIS measure. The current measure
Morphine Equivalent Dosing
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class This criteria was recommended for review by the Texas Medicaid Vendor Drug Program to ensure appropriate and safe utilization. Clinical
Abuse Deterrent Opioid Formulations Claire Saadeh, PharmD, BCOP / August 2017
Opioid Formulations Claire Saadeh, PharmD, BCOP / August 2017 Introduction 1,2 Dilemma: Providing balance between providing appropriate access to opioid products in patients who truly need them AND addressing
Acetaminophen/Aspirin/Ibuprofen Containing Immediate Release Opioid Analgesics: Quantity Limit Policy
DRUG POLICY Acetaminophen/Aspirin/Ibuprofen Containing Immediate Release Opioid Analgesics: Quantity Limit Policy BENEFIT APPLICATION Benefit determinations are based on the applicable contract language
Equianalgesic Dosing of Opioids for Pain Management
PL Detail-Document #300405 This PL Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER April 2014 Equianalgesic Dosing of Opioids for Pain Management
Session VI. SAFE Opioid Prescribing Strategies. Assessment. Fundamentals. Education. Presenter Disclosure Information. Presenting Faculty
Presenter Disclosure Information SAFE Opioid Prescribing Strategies. Assessment. Fundamentals. Education 4:15 5pm Getting the Most Clinical Insights from Specific ER/LA Product Information Sources SPEAKERS
Opioid Management Program
Opioid Management Program April 2019 What Is the Opioid Management Program? This program is based on guidelines developed by the U.S. Centers for Disease Control and Prevention (CDC). It consists of daily
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 24 June 2010
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 24 June 2010 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical
Limitations of use: Subsys may be dispensed only to patients enrolled in the TIRF REMS Access program (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.21 Subject: Subsys Page: 1 of 5 Last Review Date March 17, 2017 Subsys Description Subsys (fentanyl
** Fee-For-Service Pharmacy Provider Notice #229 May 2018 PDL Changes **
** Fee-For-Service Pharmacy Provider Notice #229 May 2018 PDL Changes ** August 03, 2018 Please be advised that the Department for Medicaid Services (DMS) is making changes to the Kentucky Medicaid Fee-For-Service
The original MED criteria can be referenced at the Texas Vendor Drug Program website located at
Morphine Equivalent Dosing (MED) Clinical Edit Criteria Drug/Drug Class Morphine Equivalent Dosing (MED) Superior HealthPlan follows the guidance of the Texas Vendor Drug Program (VDP) for all clinical
FORMULARY LIST OF COVERED DRUGS
FORMULARY LIST OF COVERED DRUGS 2018 PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN. HPMS Approved Formulary File Submission ID 00018248, Version Number #3 This formulary
Blueprint for Prescriber Continuing Education Program
CDER Final 10/25/11 Blueprint for Prescriber Continuing Education Program I. Introduction: Why Prescriber Education is Important Health care professionals who prescribe extended-release (ER) and long-acting
Hydrocodone 10mg vs oxycodone 10 mg. What is the difference between oxycontin and oxycodone hcl 1 acetaminophen with oxycodone and roxicodone 5mg
TE Te Hydrocodone 10mg vs oxycodone 10 mg What is the difference between oxycontin and oxycodone hcl 1 acetaminophen with oxycodone and roxicodone 5mg Manufacturer of oxycodone hcl 15 mg tablet side effects
paindr.com ABUSE DETERRENT FORMULATIONS CURRENT AND PIPELINE Update August, 2017 Table 1: Opioids with Abuse Deterrent Properties
ABUSE DETERRENT FORMULATIONS CURRENT AND PIPELINE Update August, 2017 Table 1: Opioids with Abuse Deterrent Properties Brand Name Generic Name Formulation Approval Year Buprenorphine Products Suboxone
``Considerations for using opioid drug therapy in workers compensation include patient safety, drug effectiveness and financial impacts
Opioids Effective Case Management Opioids RELEVANCE IN WORKERS COMP Opioids are a diverse group of drugs that represent the strongest pain medications available. They are frequently prescribed for pain
Opioid Analgesics with Abuse- Deterrent Properties: Current Data and Future Opportunities
1 National Academy of Medicine Session 4 Opioid Analgesics with Abuse- Deterrent Properties: Current Data and Future Opportunities Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center
B. Long-acting/Extended-release Opioids
4 Opioid tolerance is assumed in patients already taking fentanyl 25 mcg/hr OR daily doses of the following oral agents for 1 week: 60 mg oral morphine, 30 mg oxycodone, 8 mg hydromorphone, 25 mg of oxymorphone
Demystifying Opioid Conversion Calculations
Demystifying Opioid Conversion Calculations Stephanie Cheng, PharmD, MPH, BCGP Clinical Pharmacist Hospice Pharmacy Solutions November 28, 2018 Learning Objectives After this presentation, you should be
AVMED 4 TIER AND 5 TIER FORMULARY QUANTITY LIMIT TABLE
Effective 4/1/2018 AVMED 4 TIER AND 5 TIER FORMULARY QUANTITY LIMIT TABLE Generic Name Brand Name Quantity Limit Description Comments ABACAVIR SOLN 20 MG/ML ZIAGEN 900ml every 30 days ABACAVIR TAB 300
USE OF OPIODS AT HIGHER DOSES IN PERSONS WITHOUT CANCER: MORPHINE EQUIVALENT DOSE EDIT
BACKGROUND: USE OF OPIODS AT HIGHER DOSES IN PERSONS WITHOUT CANCER: MORPHINE EQUIVALENT DOSE EDIT Approximately 10% of patients who are prescribed opioids and seek care from multiple doctors, are prescribed
Convert hydrocodone to ms contin
Convert hydrocodone to ms contin The Borg System is 100 % Convert hydrocodone to ms contin Jan 29, 2018. HYDROcodone (Vicodin, Lortab), -, 30-45 mg, -, 3-5. OXYmorphone (Opana), 1 mg, 10 mg, 10:1, 3-6.
Slide 1. Slide 2. Slide 3. Opioid (Narcotic) Analgesics and Antagonists. Lesson 6.1. Lesson 6.1. Opioid (Narcotic) Analgesics and Antagonists
Slide 1 Opioid (Narcotic) Analgesics and Antagonists Chapter 6 1 Slide 2 Lesson 6.1 Opioid (Narcotic) Analgesics and Antagonists 1. Explain the classification, mechanism of action, and pharmacokinetics
Medication Policy Manual. Topic: Immediate-release (IR) Opioid Medication Products for Pain. Date of Origin: January 1, 2018
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Topic: Immediate-release (IR) Opioid Medication Products for Pain Policy No: dru516 Date of Origin: January